- Affiliate Assistant Professor, Global Health
- Director, HPV Vaccine Programs, Center for Vaccine Innovation and Access, PATH
PATH
Center for Vaccine Innovation and Access: Policy, Access and Introduction functional area
2201 Westlake Avenue, Suite 200
Seattle, WA 98121
United States
Select from the following:
D. Scott LaMontagne, PhD, MPH, FRSPH, CS, is an epidemiologist and director of HPV vaccine programs at PATH. He manages PATH's technical assistance team for national introductions of HPV vaccine in more than two dozen low- and middle-income countries. He is co-investigator for an HPV cost of delivery study in six countries, as well as technical officer for an alternative dosing schedule randomized controlled trial of a new bivalent HPV vaccine in Bangladesh and Ghana. He has authored and co-authored numerous papers on the clinical and operational aspects of HPV vaccine delivery in developing countries and is a recognized international expert in HPV vaccine delivery and evaluation in low-resource settings. Dr. LaMontagne has over 25 years of experience in infectious disease surveillance, operations and implementation research, public health program implementation, monitoring and evaluation, and project management for government and nongovernmental agencies at local, state, and national levels in developed and developing countries. He is a specialist in surveillance and epidemiology of human papillomavirus, Chlamydia trachomatis, tuberculosis, and sexually transmitted infections.
- PhD (Middlesex University)
- MPH (Yale University)
- BA (University of Washington)
- Japanese
- Adult Mortality
- Cervical Cancer
- Child and Adolescent Health (incl. Pediatrics)
- Cost-Effectiveness
- Delivery Logistics
- Epidemiology
- Health Policy
- HPV
- Immunizations
- Implementation Science
- Operations Research
- STDs (other than HIV)
Surveillance and epidemiology of TB and STI's
- A Phase 4 3 Randomized, Active-Comparator Controlled, Open-Label Trial to Evaluate the Immunogenicity and Safety of Alternate Two-Dose Regimens of a Bivalent Human Papillomavirus (HPV) Vaccine (Cecolin®) Compared to a Licensed Quadrivalent HPV Vaccine
- Continuing Technical Assistance to Gavi-eligible Countries for HPV Vaccine Introduction
- Evaluating the ongoing costs and operational context of national HPV vaccine delivery in six low- and middle-income countries.\
- The Single-Dose HPV Vaccine Evaluation Consortium
LaMontagne DS, Manangazira P, Marembo J, Chigodo C, Zvamashakwe C, Tshuma E, Marima E, Chindedza K, Ndlela E, and Mooney J. HPV vaccination coverage in three districts in Zimbabwe following national introduction of 0,12 month schedule among 10-14 year old girls. Vaccine (special issue) 2021; e-pub 16 July 2021. https://doi.org/10.1016/j.vaccine.2021.07.012
Tsu VD, LaMontagne DS, Atuhebwe P, Bloem PN, and Ndiaye C. National implementation of HPV vaccination programs in low-resource countries: lessons, challenges, and future prospects. Preventive Medicine 2021 Mar;144:106335. Epub 2021 Mar 4.
Bruni L, Saura A, Montoliu A, Brotons M, Alemany L, Diallo MS, Afsar OZ, LaMontagne DS, Mosina L, Contreras M, Velandia-González M, Pastore R, Gacic-Dobo M, and Bloem P. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Preventive Medicine 2021 Mar;144:106399. Epub 2020 Dec 31.
Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine (special issue) 2018; 36(32 Part A): 4761-4767.
LaMontagne DS, Bloem PJN, Brotherton JML, Gallagher KE, Badiane O, Ndiaye C. Progress in HPV vaccination in low and lower-middle income countries. International Journal of Obstetrics & Gynecology 2017; 138(S1): 7-14.